The shopper the trial describes, the dose it used, its safety file, and the shelf wording that stays inside the licence.
By IHR Editorial Team, IHR Magazine. November 10, 2026.
Women taking Pycnogenol® scored nearly 14 points better than women on placebo for bodily pain after three months, once the researchers adjusted for starting scores. The Pycnogenol® osteopenia trial, published October 12 in Frontiers in Nutrition, studied postmenopausal women with low bone density and no prescription therapy. For health retailers it is the first human quality-of-life data on the extract in a customer the bone aisle already serves.
Pycnogenol® is a standardized extract of French maritime pine bark (Pinus pinaster) by Horphag Research. Each batch carries 65 to 75 per cent procyanidins and meets the United States Pharmacopeia monograph for pine extract. Its research file spans more than 160 clinical trials and over 13,000 participants.
A large, undertreated shopper base
Osteoporosis Canada counts more than 2.3 million Canadians living with the disease, about 80 per cent of them women. Bone loss speeds up to 2 or 3 per cent a year as menopause approaches. At least one woman in three will break a bone because of it.
Treatment lags far behind diagnosis. Federal surveillance data from 2019 to 2020 show that only 21 per cent of Canadians aged 65 and over got an anti-osteoporosis prescription after a fracture. Just 15 per cent of those 40 and over had a bone density test afterwards. The Würzburg team recruited women in exactly that position: diagnosed, but not on a bone drug.
The Pycnogenol® osteopenia results on pain and vitality
Of 220 women screened, 67 were randomized. Thirty-three took 100 mg of Pycnogenol® twice daily and 34 took a matching placebo for three months. Everyone then took the extract for three more months. Average age was about 61, and roughly 9 per cent of each arm dropped out.
On the SF-36v2 health survey (bodily pain), where higher is better, the Pycnogenol® arm rose from 57.5 to 68.1. Placebo slipped from 55.4 to 51.9. The adjusted gap was statistically significant (p = 0.0106) and was still present at six months.
Vitality also improved. At three months the Pycnogenol® group scored 64.6 and the placebo group 54.4, an adjusted difference of 8.5 points.
QUALEFFO-41, a survey designed for osteoporosis patients, showed no treatment effect on its total score. Its pain domain separated only at six months, after the placebo group had switched, so that comparison measures time on product. The authors note that the trial was not sized to test quality of life, so a larger study would need to confirm the pain and vitality results.
Bone markers held steady
Bone turnover was the primary endpoint, covered in a companion paper. CTX-1, a marker of bone breakdown, fell about 11 per cent on Pycnogenol® but did not beat placebo, NutraIngredients reported. However, the CTX-1 decrease was significant compared with baseline on Pycnogenol®, while the placebo group showed no significant change.
Part II fills in the mineral picture. Calcium held at 2.39 mmol/L in both arms, and vitamin D and alkaline phosphatase did not shift. Parathyroid hormone dipped below placebo at three months, a difference that vanished after baseline adjustment.
Serum phosphate drifted from 1.20 to 1.12 mmol/L over six months, inside the 0.6 to 1.8 reference range. Higher phosphate has been linked to fracture risk in older women, yet the authors call the evidence too thin to treat the decline as protective. Rodent work had hinted at slower bone loss, and this human trial did not confirm it.
Six months of blood work came back clean
For retailers, the safety data may be the most useful part of the paper. Most earlier Pycnogenol® trials ran under six months. This one tracked the liver, kidneys, blood counts and inflammation for the full period at 200 mg a day.
AST and ALT stayed level. Glomerular filtration rate and urea did not change, and hemoglobin and white cell counts were stable. GGT, a sensitive liver marker, eased slightly in women switched from placebo. Two mild events led to dropouts, one case of dizziness on Pycnogenol® and one of vomiting on placebo.
Horphag Research funded the work through an educational grant and supplied the capsules. The authors report that the funder had no role in design, analysis or publication. Horphag’s Sébastien Bornet told NutraIngredients its women’s health portfolio covers more than 30 studies and 2,400 women.
What a store can do with it
Canada’s NPN system makes the licensed recommended use the ceiling for any label, shelf talker or staff conversation. Bone-health wording sits with ingredients such as calcium and vitamin D, which have their own monographs. One 67-person trial on wellbeing scores creates no osteoporosis claim for pine bark extract. A card reading “builds bone” exposes the store as well as the brand. Licensed Canadian Pycnogenol® products already carry approved wording for uses such as perimenopausal symptoms and knee osteoarthritis, so staff should check which claim the box on the shelf holds.
- Audit bone-aisle shelf talkers against the NPN on each product beside them, and strip treatment or fracture language.
- Place Pycnogenol® beside calcium, vitamin D and vitamin K2 as comfort and energy support for women already managing their bone density.
- Train staff to describe the trial factually, naming who was studied and for how long, and to refer treatment questions to a pharmacist.
- Give shoppers the capsule math. The trial dose equals two 100 mg capsules or four 50 mg capsules a day.
- Watch for longer studies. The authors want to know whether the pain and vitality gains last past six months.
Calcium and vitamin D have anchored the bone aisle for decades. This trial adds evidence on comfort and energy, two needs those ingredients do not address.
Related reading: Pycnogenol® cognitive research by life stage.
Frequently Asked Questions
Who was eligible for the trial?
Recruitment ran from October 2021 to January 2024 at the University of Würzburg osteology unit in Germany. Women qualified under German national guidelines for osteopenia or stable osteoporosis. Anyone with a fracture in the prior three months, a current need for drug treatment, or other supplement use was excluded. Men were eligible, but none enrolled.
Can it be combined with calcium and vitamin D?
Participants kept their normal diet, and their blood calcium and vitamin D stayed steady, but no combined formula was tested. That leaves no data on stacking products. Shoppers on prescription medication, including blood thinners, should ask a pharmacist before adding anything new.
How did researchers measure quality of life?
Two validated questionnaires were completed at the start, at three months and at six months. SF-36v2 has 36 items across eight domains, compared against population norms. QUALEFFO-41, from the International Osteoporosis Foundation, has 41 items in seven domains. Missing answers meant the SF-36 physical and mental summary scores could not be calculated.
Where can buyers read the full paper?
It is open access in Frontiers in Nutrition, volume 13, under DOI 10.3389/fnut.2026.1924081. The trial is registered with the German Clinical Trials Register as DRKS00026630. Bone turnover results appear in a separate Part I paper by the same group.
This is independent editorial analysis of peer-reviewed research and is not a product endorsement.
IHR Magazine is Canada’s business intelligence platform for the natural health, wellness and supplement trade. ihrmagazine.com
